EZH2 and breast carcinoma: Studies have reported that inhibitors for epigenetic modifications, such as DNA methyltransferase inhibitors, histone deacetylase inhibitors (HDACi) and EZH2 inhibitors (EZH2i), could reactivate ERα expression in basal-like breast cancer [57–59].